Literature DB >> 27150200

The comparison of chemerin, adiponectin and lipid profile indices in obese and non-obese adolescents.

Zahra Maghsoudi1, Roya Kelishadi2, Mohammad Javad Hosseinzadeh-Attar3.   

Abstract

AIMS: The growing prevalence of obesity and its related metabolic disorders in adolescents shows the necessity of urgent focus on the related factors. Adipocytes secretions and their pro- or anti-inflammatory roles play effective roles in adipocytes metabolism. We assessed the relation between adiponectin, chemerin and lipid profile in hit phase of life.
METHODS: This case-control study conducted on 78 adolescent girls, divided based on BMI percentile. Serum chemerin, adiponectin, lipid profile and body fat mass were measured. Data were analyzed using Pearson correlation test. The interactive relation between these variables was assessed using Structural Equation Modeling (SEM). Data were analyzed using SPSS software and AMOS software.
RESULTS: Chemerin were correlated significantly with triglyceride (r=0.584 versus r=0.319), HDL-cholestrol (r=-0.323 versus r=-0.335), LDL-cholestrol (r=0.368 versus r=0.327) and fat mass (r=0.372 versus r=0.357) in obese versus non-obese girls; while the mentioned correlation were non-significant with total cholesterol in obese group (r=0.233 versus r=0.336). Furthermore, there were significant association between adiponectin and triglyceride (r=-0.404 versus r=-0.317), HDL-cholesterol (r=0.332 versus r=0.316) and fat mass (r=-0.529 versus r=-0.346) in obese versus non-obese girls, respectively.
CONCLUSION: There were positive associations between lipid profile components and serum chemerin levels. Adiponectin levels were in positive correlation with HDL-cholesterol concentrations. Chemerin showed positive correlations with potent health threatening components of lipid profile including triglyceride and cholesterol levels in adolescents.
Copyright © 2016 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adiponectin; Adolescents; Chemerin; Lipid profile

Mesh:

Substances:

Year:  2016        PMID: 27150200     DOI: 10.1016/j.dsx.2016.01.020

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  7 in total

1.  Chemerin concentrations in infants born small for gestational age: correlations with triglycerides and parameters related to glucose homeostasis.

Authors:  Asier Léniz; Alfredo Fernández-Quintela; Marta Del Hoyo; Ignacio Díez-López; María P Portillo
Journal:  J Physiol Biochem       Date:  2020-06-16       Impact factor: 4.158

Review 2.  Inflammation Markers in Type 2 Diabetes and the Metabolic Syndrome in the Pediatric Population.

Authors:  Thomas Reinehr; Christian Ludwig Roth
Journal:  Curr Diab Rep       Date:  2018-10-18       Impact factor: 4.810

3.  Serum Chemerin Levels Correlate With Determinants of Metabolic Syndrome in Obese Children and Adolescents.

Authors:  Hong-Jun Ba; Ling-Ling Xu; You-Zhen Qin; Hong-Shan Chen
Journal:  Clin Med Insights Pediatr       Date:  2019-06-05

4.  Aerobic exercise decreases chemerin/CMKLR1 in the serum and peripheral metabolic organs of obesity and diabetes rats by increasing PPARγ.

Authors:  Xiaojing Lin; Yanan Yang; Jing Qu; Xiaohui Wang
Journal:  Nutr Metab (Lond)       Date:  2019-03-05       Impact factor: 4.169

5.  CHEMERIN AND FACTORS RELATED TO CARDIOVASCULAR RISK IN CHILDREN AND ADOLESCENTS: A SYSTEMATIC REVIEW.

Authors:  Vanessa Sequeira Fontes; Felipe Silva Neves; Ana Paula Carlos Cândido
Journal:  Rev Paul Pediatr       Date:  2018-01-15

6.  Analysis of serum chemerin concentrations in psoriatic patients in relation to metabolic abnormalities.

Authors:  Katarzyna M Chyl-Surdacka; Agnieszka Gerkowicz; Joanna Bartosińska; Małgorzata Kowal; Joanna Przepiórka-Kosińska; Gabriel Surdacki; Dorota Krasowska; Grażyna Chodorowska
Journal:  Postepy Dermatol Alergol       Date:  2019-11-12       Impact factor: 1.837

Review 7.  Chemerin as Potential Biomarker in Pediatric Diseases: A PRISMA-Compliant Study.

Authors:  Katarzyna Zdanowicz; Anna Bobrus-Chociej; Dariusz Marek Lebensztejn
Journal:  Biomedicines       Date:  2022-03-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.